FDA Gains Full Approval for Veklury Following EUA-to-Approval Transition in COVID-19 Treatment

The FDA's full approval of Veklury (remdesivir) on October 22, 2020 marked the first completed EUA-to-approval transition for a COVID-19 therapeutic, establishing a regulatory precedent that manufacturers operating under accelerated frameworks should map against their own submission strategies. For QA directors and regulatory affairs leads, the approval signals how CDER intends to apply its structured benefit-risk framework even when emergency pathways have already granted market access.

Approval was granted for adults and pediatric patients aged 12 and older weighing at least 40 kg who require hospitalization. The scope deliberately excludes the broader population previously covered under the EUA issued on May 1, 2020. Concurrently, FDA revised that EUA to extend coverage to hospitalized pediatric patients weighing 3.5 kg to less than 40 kg, or those under 12 years weighing at least 3.5 kg, preserving access where full approval data were not yet sufficient.

The evidentiary anchor for approval was the ACTT-1 trial, sponsored by the National Institute of Allergy and Infectious Diseases, which demonstrated a median time to recovery of approximately 10 days in the Veklury arm versus 15 days in the placebo group. CDER's review prioritised randomised, controlled trial data as the primary standard, consistent with its standard benefit-risk methodology under 21 CFR Part 314, regardless of the prior EUA status of the compound.

For plant heads and supply-chain leads, the approval's labelling carries direct operational weight. Veklury is restricted to administration in hospital settings or facilities capable of delivering acute inpatient-equivalent care, a constraint that affects distribution channel design and site qualification documentation. Prescribing information specifies monitoring requirements for hepatic enzyme elevation and infusion-related hypersensitivity reactions, both of which carry implications for post-market pharmacovigilance systems and adverse event reporting infrastructure.

FDA confirmed that post-approval safety monitoring obligations apply in full, consistent with its standard oversight posture for all approved products. Manufacturers navigating similar EUA-to-approval transitions should treat the Veklury pathway as a reference case for how CDER manages population scope adjustments, concurrent EUA revisions, and the evidentiary threshold required to convert emergency access into a durable approval.

The Veklury label and the Combined Cross-Discipline Team Leader, Division Director, and ODE Director Summary Review remain publicly available as primary reference documents for regulatory teams benchmarking their own submission packages against CDER's documented decision logic.

Source: FDA Center for Drug Evaluation and Research via FDA.gov, October 22, 2020; republished in FDA What's New: Drugs RSS Feed, July 6, 2026.